Pharmacokinetics and Pharmacogenetics-based Adaptive Dosing of 5-fu (5-Fluorouracile) in Head & Neck Cancer Patient Undergoing Docetaxel, Cisplatin, 5-Fluorouracile (=TPF) Therapy

Inclusion Criteria: * Age \> 18 and ≤ 80 years. * Squamous cell carcinoma of the head and neck (oral cavity, oropharynx, hypopharynx, larynx, nasopharynx). * Locally advanced stage (III, IVa or IVb). * The patient must have received the information note and signing the informed consent, as well as being spent in multidisciplinary meeting after which treatment with TPF (Docetaxel, Cisplatin, 5-Fluorouracile) induction chemotherapy was proposed. * Performance Status less than or equal to 2 (WHO performance index). * The patient must be affiliated to a social security scheme and followed in one of the participating centers. * Patients polymorphonuclear neutrophil greater than or equal to 1000 / mm3, platelets greater than or equal to 100 000 / mm3, hemoglobin greater than or equal to 8 g / dl, transaminases less than or equal to 1.5 times the normal, total bilirubin or equal 1.5 times the normal creatinine clearance in the upper or equal to 50 ml / min Modification of Diet in Renal Disease (MDRD) * Satisfactory heart function * Patients must be able to submit to the rhythm of visits, treatment plan, laboratory balances and other study procedures. Exclusion Criteria: * Patient \> 80 years. * Patients with uncontrolled infection that could compromise participation in the study. * Patients with other serious concomitant diseases and / or uncontrolled that could compromise participation in the study. * Patients with serum bilirubin\> under limit normal and / or Alanine Transamina…